StockMarketWire.com - AstraZeneca revealed positive results from its clinical trial for its triple-combination drug for lung disease sufferers.

The trial met its primary endpoint showing that the company's triple-combination treatment reduced the risk of severe or moderate exacerbations in patients with chronic obstructive pulmonary disease (COPD), compared with dual-combination therapies.

'Exacerbations are devastating events for patients and can lead to a permanent loss of lung function,' said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D.

'The Phase III ETHOS trial builds on the Phase III KRONOS data which together show Breztri Aerosphere's ability to reduce exacerbation risk in a broad range of patients with COPD, irrespective of whether they have had an exacerbation in the previous twelve months.'

'The Phase III ETHOS trial builds on the Phase III KRONOS data which together show Breztri Aerosphere's ability to reduce exacerbation risk in a broad range of patients with COPD.'




Story provided by StockMarketWire.com